EDD

 

Benefit of Coffee

 Not only can your daily cup of joe help you feel more energized, burn fat and improve physical performance, it may also lower your risk of several conditions, such as type 2 diabetes, cancer and Alzheimer's and Parkinson's disease. In fact, coffee may even boost longevity.Sep 20, 2018

SUMMARYCaffeine blocks an inhibitory neurotransmitter in your brain, which causes a stimulant effect. This improves energy levels, mood and various aspects of brain function.

Performance

Caffeine stimulates your nervous system, signaling fat cells to break down body fat (13Trusted Source, 14).

But it also increases epinephrine (adrenaline) levels in your blood (15Trusted Source, 16Trusted Source).

This is the fight-or-flight hormone, which prepares your body for intense physical exertion.

Caffeine breaks down body fat, making free fatty acids available as fuel (17Trusted Source, 18).

Given these effects, it’s unsurprising that caffeine can improve physical performance by 11–12%, on average (20Trusted Source, 29).

Therefore, it makes sense to have a strong cup of coffee about half an hour before you head to the gym.

 May Protect You From Alzheimer’s Disease and Dementia

Alzheimer’s disease is the most common neurodegenerative disease and the leading cause of dementia worldwide.

This condition usually affects people over 65, and there is no known cure.

However, there are several things you can do to prevent the disease from occurring in the first place.

This includes the usual suspects like eating healthy and exercising, but drinking coffee may be incredibly effective as well.

Several studies show that coffee drinkers have up to a 65% lower risk of Alzheimer’s disease (28, 29Trusted Source).

SUMMARYCoffee drinkers have a much lower risk of getting Alzheimer’s disease, which is a leading cause of dementia worldwide.

correction to Data Week Ahead on Dec. 4

 

correction to Data Week Ahead on Dec. 4

12/5/20 11:17 AM ET (Dow Jones)Print

The University of Michigan preliminary consumer survey (Consumer Sentiment) will be released Friday, Dec. 11. "Consumer Price Index and Producer Price Index on Tap -- Data Week Ahead" published on Dec. 4 at 2:14 p.m. ET incorrectly labeled the event as Consumer Price Index.

(END) Dow Jones Newswires

December 05, 2020 11:17 ET (16:17 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Benzinga Pro's Top 5 Stocks To Watch For Friday, Dec. 4, 2020: BNTX, CRON, MDB, CIIC, CHWY

 

Benzinga Pro's Top 5 Stocks To Watch For Friday, Dec. 4, 2020: BNTX, CRON, MDB, CIIC, CHWY

12/4/20 8:35 AM ET (Benzinga)Print

Today's 5 Stock Ideas: 

• BioNTech (BNTX) - The stock was down ahead of Friday's opening bell following news from COVID-19 vaccine partner, Pfizer (PFE). Pfizer warned it will ship only half of the COVID-19 vaccines planned this year. The company cited a supply-chain issue. CNBC pharma reporter, Meg Tirrell, called the supply chain issues "nothing new" and noted Pfizer warned on Nov. 9 of a reduced forecast for supply. 
• Cronos Group (CRON) - Shares have been up more than 20% over the last couple weeks ahead of a Friday vote in the US House of Representatives related to marijuana legalization. 
• MongoDB (MDB) - Will report Q3 earnings after market close on Tuesday.
• CIIG Merger (CIIC) - This special purpose acquisition corporation (SPAC) received some love from Jim Cramer on "Mad Money" Thursday evening. Cramer called the company's merger partner "the son of Tesla."
• Chewy (CHWY) - To publish quarterly results after market close on Tuesday. Analysts expect a quarterly loss of $0.13 per share on sales of $1.72 billion.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rig

Novel AML patient selection assay for AMV564, Amphivena's lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting

 

Novel AML patient selection assay for AMV564, Amphivena's lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting

Today 7:00 AM ET (PR NewsWire)Print

Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, today presented data on a novel assay for selection of acute myeloid leukemia (AML) patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020), taking place virtually from December 5-8, 2020.

This novel assay could identify patients most likely to experience deeper and more durable responses with AMV564 therapy

AMV564 is the lead candidate from the AMPHIVENA ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers, and has been studied in 2 Ph1 clinical studies in relapsed/refractory AML (NCT03144245) and in patients with advanced solid tumor malignancies (NCT04128423). AMV564 selectively depletes both myeloid derived suppressor cells (MDSC) and leukemic blasts via avid binding to clustered CD33, has been well tolerated with no dose-limiting toxicities reported and has shown single-agent activity across both R/R AML and solid tumors.

The assay leverages the selectivity of AMV564 in a screening format to identify AML patients in whom leukemic blasts are expressing CD33 in a predominantly clustered configuration. "While AMV564 has demonstrated early signs of efficacy and anti-leukemic blast activity across an unselected relapsed/refractory AML population, this novel assay could identify patients most likely to experience deeper and more durable responses with AMV564 monotherapy", said Curtis Ruegg, Ph.D., President and CEO of Amphivena.

Details of the Presentation:

Title: Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection Authors: Sarde, A. et al. Abstract Number: 1976 Session: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II Poster Viewing: Sunday, December 6, 2020: 7:00 AM-3:30 PM EST

The abstract and presentation are available on the ASH Annual Meeting, and Amphivena websites.

About AMV564

AMV564 relieves immune suppression via targeted depletion of immunosuppressive myeloid derived suppressor cells (MDSC) and drives T cell activation and polarization to restore anti-cancer immunity. To date, over 95 patients have received AMV564 across three Phase 1 clinical trials for patients with solid tumors, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS).

About Amphivena Therapeutics, Inc.

Amphivena Therapeutics, Inc. is a privately held, clinical-stage, oncology company based in South San Francisco, CA with a mission to restore anti-cancer immunity in patients and to take cancer treatment beyond the limits of immunotherapy. Our proprietary Amphivena ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers is designed to selectively relieve immune suppression and drive T-cell activation/polarization in patients. The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of MDSC, known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives improved T cell effector function. AMV564-induced immune restoration is optimized by targeting the lymphoid tissues, through subcutaneous delivery, where immunoregulation occurs. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to offer new treatment options to cancer patients underserved by immunotherapy.

Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC.

Contact:Alicia Chung, Corporate Developmentachung@amphivena.com +1 650 499-3178info@amphivena.com

https://c212.net/c/img/favicon.png?sn=SF14461&sd=2020-12-06

View original content:http://www.prnewswire.com/news-releases/novel-aml-patient-selection-assay-for-amv564-amphivenas-lead-therapeutic-in-hematology-presented-at-the-62nd-american-society-of-hematology-ash-2020-annual-meeting-301186856.html

SOURCE Amphivena Therapeutics

https://rt.prnewswire.com/rt.gif?NewsItemId=SF14461&Transmission_Id=202012060700PR_NEWS_USPR_____SF14461&DateId=20201206